Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 229

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Open access
Yuan, Jianda, Hegde, Priti S., Clynes, Raphael, Foukas, Periklis G., Harari, Alexandre, Kleen, Thomas O., Kvistborg, Pia, Maccalli, Cristina, Maecker, Holden T., Page, David B., Robins, Harlan, Song, Wenru, Stack, Edward C., Wang, Ena, Whiteside, Theresa L., Zhao, Yingdong, Zwierzina, Heinz, Butterfield, Lisa H., Fox, Bernard A.·2016·Journal for ImmunoTherapy of Cancer
DOI 10.1186/s40425-016-0107-3
Open this paper in CoChat — free account

Abstract

The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-016-0107-3

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 229

Metadata

Authors
Yuan, J., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., Robins, H., Song, W., Stack, E. C., Wang, E., Whiteside, T. L., Zhao, Y., Zwierzina, H., Butterfield, L. H., & Fox, B. A.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2016-01-19
Volume
4
Issue
1
Pages
3-3
ISSN
2051-1426 (ISSN-L)
DOI
10.1186/s40425-016-0107-3
OpenAlex
W2276555358
Cited by
229
References
49
FWCI
19.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel technologies and emerging biomarkers for personalized cancer immunotherapy. https://app.cochat.ai/papers/10.1186/s40425-016-0107-3
The paper
Yuan, J., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., Robins, H., Song, W., Stack, E. C., Wang, E., Whiteside, T. L., Zhao, Y., Zwierzina, H., Butterfield, L. H., & Fox, B. A. (2016). Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-016-0107-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.